Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

822 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Sasaki Y, Hamaguchi T, Yamada Y, Takahashi N, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Nagai Y, Taniguchi H, Boku N, Ushijima T, Shimada Y. Sasaki Y, et al. Among authors: shoji h. Asian Pac J Cancer Prev. 2016;17(2):539-43. doi: 10.7314/apjcp.2016.17.2.539. Asian Pac J Cancer Prev. 2016. PMID: 26925640 Free article.
Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients.
Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Tada K, et al. Among authors: shoji h. Cancer Immunol Res. 2016 Jul;4(7):592-9. doi: 10.1158/2326-6066.CIR-15-0298. Epub 2016 Apr 28. Cancer Immunol Res. 2016. PMID: 27197061
A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab.
Takahashi N, Iwasa S, Fukahori M, Sudo K, Sasaki Y, Shoji H, Honma Y, Okita NT, Takashima A, Hamaguchi T, Boku N, Shimada Y, Honda K, Yamada T, Yamada Y. Takahashi N, et al. Among authors: shoji h. Cancer Chemother Pharmacol. 2016 Sep;78(3):567-75. doi: 10.1007/s00280-016-3111-x. Epub 2016 Jul 20. Cancer Chemother Pharmacol. 2016. PMID: 27438067 Clinical Trial.
The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy.
Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Heike Y, Hamaguchi T. Shoji H, et al. Oncotarget. 2017 May 30;8(56):95083-95094. doi: 10.18632/oncotarget.18297. eCollection 2017 Nov 10. Oncotarget. 2017. PMID: 29221113 Free PMC article.
A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma.
Hiramoto S, Kato K, Shoji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N. Hiramoto S, et al. Among authors: shoji h. Int J Clin Oncol. 2018 Jun;23(3):466-472. doi: 10.1007/s10147-018-1239-x. Epub 2018 Jan 20. Int J Clin Oncol. 2018. PMID: 29353337 Clinical Trial.
Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study.
Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Shimada Y, Yamada Y. Honma Y, et al. Among authors: shoji h. Br J Radiol. 2018 Sep;91(1089):20180259. doi: 10.1259/bjr.20180259. Epub 2018 Jun 27. Br J Radiol. 2018. PMID: 29916721 Free PMC article.
822 results